Concepedia

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

Anas Younes, Julie M. Vose, Andrew D. Zelenetz, Mitchell R. Smith, Howard A. Burris, Stephen M. Ansell, J Klein, Wendy Halpern, R. Miceli, Elizabeth Kumm,

British Journal of Cancer · 2010 · 129 citations · 15 references

DOIFull text

Open access

Concepts

References

15

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

Anthony W. Tolcher, Monica Mita, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 311 citations · Full text

, , +17

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

Laurie Pukac, Palanisamy Kanakaraj, Robin Humphreys et al. · British Journal of Cancer · 2005 · 300 citations · Full text

, , +17

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

Sebastién J. Hotte, Hal W. Hirte, Eric X. Chen et al. · Clinical Cancer Research · 2008 · 189 citations

, , +17

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

Tanja Trarbach, Markus Moehler, Volker Heinemann et al. · British Journal of Cancer · 2010 · 180 citations · Full text

, , +17

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell death

Georgios Georgakis, Yang Li, Robin Humphreys et al. · British Journal of Haematology · 2005 · 169 citations

, , +17